Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis

A Proof of Concept, Investigator Blinded Study to Evaluate the Efficacy and Safety of a Novel Combination of a Home Narrow Band Ultraviolet B (NBUVB) Lamp With an Occlusive Dressing in Adult Subjects With Mild to Moderate Psoriasis Vulgaris

This is a proof of concept, investigator blinded study to evaluate the efficacy and safety of a novel combination of a home narrow band ultraviolet B (NBUVB) lamp with an occlusive dressing in adult subjects with mild to moderate psoriasis vulgaris. Four interpatient arms will be used to compare the efficacy of combination of NBUVB with an occlusive dressing to the light alone and to dressing alone and no treatment. Ten patients will be enrolled in this 6 weeks study.

Study Overview

• Status: Unknown
• Conditions: Psoriasis
• Intervention / Treatment: Device: Occlusive Dressing; Device: Luma Light; Device: Luma Light System

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Santa Rosa, California, United States, 95403
      • Recruiting
      • Redwood Family Dermatology
      • Contact: Liza Marie; Phone Number: 707-755-3946; Email: liza@redwoodfamilyderm.com
      • Principal Investigator: Jeffrey Sugarman, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female of any race, 18 to 65 (inclusive) years of age.
• Verbal and written informed consent obtained from the subject.
• Has a clinical diagnosis of mild to moderate psoriasis at the Screening and Baseline visits.
• Has an IGA score of 2 or 3.
• Target plaque assessment (TPA) score between 6-9 and a score of at least 2 for each of the 3 different psoriasis signs and symptoms (erythema, plaque elevation, and scaling)
• Has at least 4 plaques of at least 10 cm2 with TPA scores not differing from each other by a score of more than 1
• Is in good general health as determined by the Investigator based on the subject's medical history, vital signs and physical examination.
• Females of childbearing potential must have negative urine pregnancy test results.
• Females of childbearing potential agree to use acceptable methods of contraception from the screening visit continuously until 30 days after end of treatment.
• Subject agrees to use only the Sponsor provided cleanser and lotion during the study period.
• Subject is willing and able to return for all study visits.

Exclusion Criteria:

• Presence of psoriasis that was previously treated with prescription medications prior to the Screening visit and was non-responsive to treatment, as determined by the Investigator.
• Presence of any concurrent skin condition that could interfere with the evaluation of the study device, as determined by the Investigator.
• Female who is pregnant, nursing an infant, or planning a pregnancy during the study period.
• Treatment with any investigational drug or device within 30 days or 5 half-lives (whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial with an investigational drug or device.
• History of melanoma.
• Subject has any medical, social or psychological conditions that, in the opinion of the Investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Non-treatment Control; Control arm will not have any intervention
Active Comparator: Occlusive Dressing; An off-the-shelf dressing occlusive dressing will be used as an active comparator.	Device: Occlusive Dressing; Off-the-shelf occlusive dressing
Active Comparator: Luma Light; A NBUVB light will be used as an active comparator.	Device: Luma Light; NBUVB light
Experimental: Luma Light System; The experimental arm will be a combination of an occlusive dressing and NBUVB light.	Device: Luma Light System; The Luma Light System combines a NBUVB light with an occlusive dressing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Target Plaque Assessment	Local efficacy will be evaluated with a 0-4 point scale for three signs and symptoms of psoriasis: erythema, plaque elevation, and scaling.	6 weeks
Local Skin Reactions	Tolerability will be evaluated through assessment of selected local signs and symptoms at the article-application site: Burning/stinging, pain and pruritus. Each sign or symptom will be graded at Baseline and each subsequent visit using a 0-3 scale (0 = none, 1 = mild, 2 = moderate, or 3 = severe).	6 weeks

Collaborators and Investigators

• Sponsor: Illumicure Inc

Study record dates

Study Major Dates

• Study Start: May 1, 2015
• Primary Completion (Anticipated): September 1, 2015

Study Registration Dates

• First Submitted: May 14, 2015
• First Submitted That Met QC Criteria: May 15, 2015
• First Posted (Estimate): May 18, 2015

Study Record Updates

• Last Update Posted (Estimate): May 20, 2015
• Last Update Submitted That Met QC Criteria: May 18, 2015
• Last Verified: May 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: L-001